MedWatch

World's largest public-private antibiotic fund unveils first investments

The AMR Action Fund, established in the summer of 2020 by an extensive consortium of some of the world’s leading pharmaceutical companies including Novo Nordisk, is ready to announce its first two investments in the first against antimicrobial resistance (AMR).

Photo: Daniel Karmann/AP/Ritzau Scanpix

Around two years after the AMR Action Fund came into existence with the goal of aiding the development of new antibiotic drugs, the fund has announced its first two investments, a press release reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs